TY - JOUR
T1 - Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice
AU - Aragaw, Wassihun Wedajo
AU - Roubert, Christine
AU - Fontaine, Evelyne
AU - Lagrange, Sophie
AU - Zimmerman, Matthew D.
AU - Dartois, Véronique
AU - Gengenbacher, Martin
AU - Dick, Thomas
N1 - Funding Information:
Research reported in this work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award R01AI132374.
Publisher Copyright:
© 2022 Aragaw et al.
PY - 2022/1
Y1 - 2022/1
N2 - Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.
AB - Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.
KW - DnaN
KW - Griselimycin
KW - Mycobacterium abscessus
KW - NTM
KW - Nontuberculous mycobacteria
UR - http://www.scopus.com/inward/record.url?scp=85123069190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123069190&partnerID=8YFLogxK
U2 - 10.1128/AAC.01400-21
DO - 10.1128/AAC.01400-21
M3 - Article
C2 - 34723632
AN - SCOPUS:85123069190
SN - 0066-4804
VL - 66
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 1
M1 - e01400-21
ER -